Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Insulin in Psychotic Disorders
NCT03943537Phase 2Completed
- Sponsor
- McLean Hospital
- Start
- Oct 2019
- Primary completion
- Feb 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of intranasal insulin in schizophrenia, schizoaffective disorder, bipolar disorder (BD), sponsored by McLean Hospital. Started Oct 2019; status: completed.
02
Drugs
intranasal insulin
03
Conditions
schizophreniaschizoaffective disorderbipolar disorder (BD)
Beyond the preview
Go deeper on NCT03943537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03943537.